Claude Nicaise - 20 Sep 2022 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Director
Signature
/s/ Jason Minio, Attorney-in-Fact
Issuer symbol
GANX
Transactions as of
20 Sep 2022
Net transactions value
$0
Form type
4
Filing time
22 Sep 2022, 16:08:24 UTC
Previous filing
08 Mar 2022
Next filing
08 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Stock Option (right to buy) Award $0 +10,500 $0.000000 10,500 20 Sep 2022 Common Stock 10,500 $3.50 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests fully on the day before the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service as a director of the Issuer.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney